

Manuscript file: 17519

Dear Editor,

We thank you for giving us the opportunity of resubmitting our manuscript entitled **“Is there still a place for docetaxel rechallenge in prostate cancer?”** to **WJCO**.

We accurately read the constructive comments of the reviewers and we have now revised the paper according to their suggestions. We mark revised words or sentences by single underlining. Herewith we list the changes we made to clarify their reasonable doubts:

Reviewer 1

Dear Author, The review is well written and added to our knowledge. It offers new insights on treatment. As such, the manuscript is given a higher rating.

Thank you.

Reviewer 2

Well written concise editorial.

Thank you.

Reviewer 3

The title is a bit misleading as there is no direct comparison with the new drugs for mCRPC. The Introduction section could be reduced and the main text which is relevant to the topic could be enriched. The following reference could be added in the revised manuscript in order to stress the cheaper option of the rechallenge therapy: The economics of abiraterone acetate for castration-resistant prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):175-9.

According your suggestion, i have changed the title. I have reduced the introduction and added in the main text. Finally, i have added the reference, which you have suggested.

Reviewer 4

Excellent review, well documented, up-to-date, needing minor language polishing.

The language has been edited.

EDITOR COMMENTS

We have changed according editor needs.

